SYRE
SYRE
NASDAQ · Biotechnology

Spyre Therapeutics Inc

$42.77
+1.52 (+3.68%)
As of Mar 24, 1:30 PM ET ·
Financial Highlights (FY 2025)
Revenue
469.29M
Net Income
-23,759,261
Gross Margin
48.9%
Profit Margin
-5.1%
Rev Growth
+18.1%
D/E Ratio
0.73
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 48.9% 48.9% 48.9%
Operating Margin -5.5% -4.7% -4.8%
Profit Margin -5.1% -5.6% -4.9%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 469.29M 433.92M 481.69M
Gross Profit 229.54M 212.24M 235.60M
Operating Income -25,683,158 -20,310,769 -22,957,643
Net Income -23,759,261 -24,167,490 -23,392,315
Gross Margin 48.9% 48.9% 48.9%
Operating Margin -5.5% -4.7% -4.8%
Profit Margin -5.1% -5.6% -4.9%
Rev Growth +18.1% +19.4% +22.5%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 979.55M 1.12B 1.21B
Total Equity 1.33B 1.29B 1.56B
D/E Ratio 0.73 0.87 0.77
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA -33,340,073 -28,197,061 -36,465,134
Free Cash Flow -26,670,161 -19,444,681 -29,871,207